Following CE mark approval, the company says European surgeons already performed the first series of cases with EnCompass. The system received FDA 510(k) clearance and launched in the U.S. in 2022.
Mason, Ohio-based AtriCure designed EnCompass for the ablation of cardiac tissue during cardiac surgery to make concomitant surgical ablations more efficient. It allows physicians to perform a comprehensive epicardial ablation of the left atrium in just a few minutes.
The platform includes parallel closure, uniform pressure and custom power using Synergy radiofrequency (RF). AtriCure said the new features of the EnCompass Clamp allow for easier placement using a magnetic guide, enabling more efficient procedures by minimizing tissue dissection.
“Launching our EnCompass clamp in Europe represents a significant expansion of our product line internationally,” said Michael Carrel, president and CEO of AtriCure. “We have seen this product have a positive impact in the United States over the last two years by advancing treatment concomitant to cardiac surgery. We are excited to offer this safe, innovative, and effective therapy to patients and our physician partners in Europe.”
